Context-dependent role of IL-18 in cancer biology and counter-regulation by IL-18BP

Journal of Leukocyte Biology

Volumn 97, Issue 4, 2015, Pages 665-675

  Fabbi, Marina ^a   Carbotti, Grazia ^a   Ferrini, Silvano ^a  

^a UNIVERSITY OF GENOA   (Italy)

Author keywords

Cancer immunotherapy; Immune regulation; Th1 response

Indexed keywords

CASPASE; INFLAMMASOME; INTERLEUKIN 18; INTERLEUKIN 1BETA CONVERTING ENZYME; INTERLEUKIN 18 PROTEIN, HUMAN; INTERLEUKIN 18 RECEPTOR; INTERLEUKIN-18 BINDING PROTEIN; PROTEIN PRECURSOR; SIGNAL PEPTIDE;

ANTIGEN PRESENTATION; ANTINEOPLASTIC ACTIVITY; CANCER IMMUNOTHERAPY; HUMAN; NATURAL KILLER CELL; NEOPLASM; NONHUMAN; PRIORITY JOURNAL; REGULATORY MECHANISM; REVIEW; SIGNAL TRANSDUCTION; ADOPTIVE IMMUNOTHERAPY; ANIMAL; BIOLOGICAL MODEL; COCARCINOGENESIS; DEFICIENCY; DISEASE COURSE; DRUG SCREENING; ENZYME ACTIVATION; EXPERIMENTAL NEOPLASM; GENETICS; IMMUNOLOGY; IMMUNOTHERAPY; INFLAMMATION; KNOCKOUT MOUSE; LYMPHOCYTE SUBPOPULATION; METABOLISM; MICROBIOLOGY; MOUSE; NEOPLASMS; PHAGOCYTE; PHASE 1 CLINICAL TRIAL (TOPIC); PHYSIOLOGY; PROMOTER REGION; RANDOMIZED CONTROLLED TRIAL (TOPIC); TRANSPLANTATION; VIRUS INFECTION;

ANIMALS; CASPASE 1; CLINICAL TRIALS, PHASE I AS TOPIC; COCARCINOGENESIS; DISEASE PROGRESSION; DRUG SCREENING ASSAYS, ANTITUMOR; ENZYME ACTIVATION; HUMANS; IMMUNOTHERAPY; IMMUNOTHERAPY, ADOPTIVE; INFLAMMASOMES; INFLAMMATION; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; INTERLEUKIN-18; KILLER CELLS, NATURAL; LYMPHOCYTE SUBSETS; MICE; MICE, KNOCKOUT; MODELS, IMMUNOLOGICAL; NEOPLASMS; NEOPLASMS, EXPERIMENTAL; PHAGOCYTES; PROMOTER REGIONS, GENETIC; PROTEIN PRECURSORS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECEPTORS, INTERLEUKIN-18; VIRUS DISEASES;

EID: 84929167350     PISSN: 07415400     EISSN: 19383673     Source Type: Journal    
DOI: 10.1189/jlb.5RU0714-360RR     Document Type: Review

References (111)

1. Garlanda, C., Dinarello, C. A., Mantovani, A. (2013) The interleukin-1 family: back to the future. Immunity 39, 1003-1018.
2. Okamura, H., Tsutsi, H., Komatsu, T., Yutsudo, M., Hakura, A., Tanimoto, T., Torigoe, K., Okura, T., Nukada, Y., Hattori, K., Akita, K., Namba, M., Tanabe, F., Konishi, K., Fukuda, S., Kurimoto, M. (1995) Cloning of a new cytokine that induces IFN-gamma production by T cells. Nature 378, 88-91.
3. Puren, A. J., Fantuzzi, G., Dinarello, C. A. (1999) Gene expression, synthesis, and secretion of interleukin 18 and interleukin 1beta are differentially regulated in human blood mononuclear cells and mouse spleen cells. Proc. Natl. Acad. Sci. USA 96, 2256-2261.
4. Zitvogel, L., Kepp, O., Galluzzi, L., Kroemer, G. (2012) Inflammasomes in carcinogenesis and anticancer immune responses. Nat. Immunol. 13, 343-351.
5. Jacobs, S. R., Damania, B. (2012) NLRs, inflammasomes, and viral infection. J. Leukoc. Biol. 92, 469-477.
6. Boraschi, D., Tagliabue, A. (2013) The interleukin-1 receptor family. Semin. Immunol. 25, 394-407.
7. Lee, J. K., Kim, S. H., Lewis, E. C., Azam, T., Reznikov, L. L., Dinarello, C. A. (2004) Differences in signaling pathways by IL-1beta and IL-18. Proc. Natl. Acad. Sci. USA 101, 8815-8820.
8. Dinarello, C. A., Fantuzzi, G. (2003) Interleukin-18 and host defense against infection. J. Infect. Dis. 187 (Suppl 2), S370-S384.
9. Gracie, J. A., Robertson, S. E., McInnes, I. B. (2003) Interleukin-18. J. Leukoc. Biol. 73, 213-224.
10. van de Veerdonk, F. L., Netea, M. G., Dinarello, C. A., Joosten, L. A. (2011) Inflammasome activation and IL-1b and IL-18 processing during infection. Trends Immunol. 32, 110-116.
11. Kinoshita, M., Miyazaki, H., Ono, S., Seki, S. (2013) Immunoenhancing therapy with interleukin-18 against bacterial infection in immunocompromised hosts after severe surgical stress. J. Leukoc. Biol. 93, 689-698.
12. Wei, X. Q., Leung, B. P., Niedbala, W., Piedrafita, D., Feng, G. J., Sweet, M., Dobbie, L., Smith, A. J., Liew, F. Y. (1999) Altered immune responses and susceptibility to Leishmania major and Staphylococcus aureus infection in IL-18-deficient mice. J. Immunol. 163, 2821-2828.
13. Liu, B., Mori, I., Hossain, M. J., Dong, L., Takeda, K., Kimura, Y. (2004) Interleukin-18 improves the early defence system against influenza virus infection by augmenting natural killer cell-mediated cytotoxicity. J. Gen. Virol. 85, 423-428.
14. Tanaka-Kataoka, M., Kunikata, T., Takayama, S., Iwaki, K., Ohashi, K., Ikeda, M., Kurimoto, M. (1999) In vivo antiviral effect of interleukin 18 in a mouse model of vaccinia virus infection. Cytokine 11, 593-599.
15. Takeda, K., Tsutsui, H., Yoshimoto, T., Adachi, O., Yoshida, N., Kishimoto, T., Okamura, H., Nakanishi, K., Akira, S. (1998) Defective NK cell activity and Th1 response in IL-18-deficient mice. Immunity 8, 383-390.
16. Fehniger, T. A., Shah, M. H., Turner, M. J., VanDeusen, J. B., Whitman, S. P., Cooper, M. A., Suzuki, K., Wechser, M., Goodsaid, F., Caligiuri, M. A. (1999) Differential cytokine and chemokine gene expression by human NK cells following activation with IL-18 or IL-15 in combination with IL-12: implications for the innate immune response. J. Immunol. 162, 4511-4520.
17. Mailliard, R. B., Alber, S. M., Shen, H., Watkins, S. C., Kirkwood, J. M., Herberman, R. B., Kalinski, P. (2005) IL-18-induced CD83+CCR7+ NK helper cells. J. Exp. Med. 202, 941-953.
18. Wong, J. L., Berk, E., Edwards, R. P., Kalinski, P. (2013) IL-18-primed helper NK cells collaborate with dendritic cells to promote recruitment of effector CD8+ T cells to the tumor microenvironment. Cancer Res. 73, 4653-4662.
19. Wong, J. L., Mailliard, R. B., Moschos, S. J., Edington, H., Lotze, M. T., Kirkwood, J. M., Kalinski, P. (2011) Helper activity of natural killer cells during the dendritic cell-mediated induction of melanoma-specific cytotoxic T cells. J. Immunother. 34, 270-278.
20. Bellora, F., Castriconi, R., Doni, A., Cantoni, C., Moretta, L., Mantovani, A., Moretta, A., Bottino, C. (2012) M-CSF induces the expression of a membrane-bound form of IL-18 in a subset of human monocytes differentiating in vitro toward macrophages. Eur. J. Immunol. 42, 1618-1626.
21. Bellora, F., Castriconi, R., Dondero, A., Pessino, A., Nencioni, A., Liggieri, G., Moretta, L., Mantovani, A., Moretta, A., Bottino, C. (2014) TLR activation of tumor-associated macrophages from ovarian cancer patients triggers cytolytic activity of NK cells. Eur. J. Immunol. 44, 1814-1822.
22. Yoshimoto, T., Mizutani, H., Tsutsui, H., Noben-Trauth, N., Yamanaka, K., Tanaka, M., Izumi, S., Okamura, H., Paul, W. E., Nakanishi, K. (2000) IL-18 induction of IgE: dependence on CD4+ T cells, IL-4 and STAT 6. Nat. Immunol. 1, 132-137.
23. Yoshimoto, T., Tsutsui, H., Tominaga, K., Hoshino, K., Okamura, H., Akira, S., Paul, W. E., Nakanishi, K. (1999) IL-18, although antiallergic when administered with IL-12, stimulates IL-4 and histamine release by basophils. Proc. Natl. Acad. Sci. USA 96, 13962-13966.
24. Kroeger, K. M., Sullivan, B. M., Locksley, R. M. (2009) IL-18 and IL-33 elicit Th2 cytokines from basophils via a MyD88- and p38alphadependent pathway. J. Leukoc. Biol. 86, 769-778.
25. Nakanishi, K., Yoshimoto, T., Tsutsui, H., Okamura, H. (2001) Interleukin-18 is a unique cytokine that stimulates both Th1 and Th2 responses depending on its cytokine milieu. Cytokine Growth Factor Rev. 12, 53-72.
26. Mills, K. H., Dungan, L. S., Jones, S. A., Harris, J. (2013) The role of inflammasome-derived IL-1 in driving IL-17 responses. J. Leukoc. Biol. 93, 489-497.
27. Lalor, S. J., Dungan, L. S., Sutton, C. E., Basdeo, S. A., Fletcher, J. M., Mills, K. H. (2011) Caspase-1-processed cytokines IL-1beta and IL-18 promote IL-17 production by gammadelta and CD4 T cells that mediate autoimmunity. J. Immunol. 186, 5738-5748.
28. Novick, D., Elbirt, D., Miller, G., Dinarello, C. A., Rubinstein, M., Sthoeger, Z. M. (2010) High circulating levels of free interleukin-18 in patients with active SLE in the presence of elevated levels of interleukin- 18 binding protein. J. Autoimmun. 34, 121-126.
29. Migliorini, P., Anzilotti, C., Pratesi, F., Quattroni, P., Bargagna, M., Dinarello, C. A., Boraschi, D. (2010) Serum and urinary levels of IL-18 and its inhibitor IL-18BP in systemic lupus erythematosus. Eur. Cytokine Netw. 21, 264-271.
30. Gabay, C., McInnes, I. B. (2009) The biological and clinical importance of the ‘new generation’ cytokines in rheumatic diseases. Arthritis Res. Ther. 11, 230.
31. Monteleone, G., Fina, D., Caruso, R., Pallone, F. (2006) New mediators of immunity and inflammation in inflammatory bowel disease. Curr. Opin. Gastroenterol. 22, 361-364.
32. Dinarello, C. A., Novick, D., Kim, S., Kaplanski, G. (2013) Interleukin-18 and IL-18 binding protein. Front. Immunol. 4, 289.
33. Novick, D., Kim, S. H., Fantuzzi, G., Reznikov, L. L., Dinarello, C. A., Rubinstein, M. (1999) Interleukin-18 binding protein: a novel modulator of the Th1 cytokine response. Immunity 10, 127-136.
34. Kim, S. H., Eisenstein, M., Reznikov, L., Fantuzzi, G., Novick, D., Rubinstein, M., Dinarello, C. A. (2000) Structural requirements of six naturally occurring isoforms of the IL-18 binding protein to inhibit IL-18. Proc. Natl. Acad. Sci. USA 97, 1190-1195.
35. Fantuzzi, G., Banda, N. K., Guthridge, C., Vondracek, A., Kim, S. H., Siegmund, B., Azam, T., Sennello, J. A., Dinarello, C. A., Arend, W. P. (2003) Generation and characterization of mice transgenic for human IL-18-binding protein isoform a. J. Leukoc. Biol. 74, 889-896.
36. Lonnemann, G., Novick, D., Rubinstein, M., Dinarello, C. A. (2003) Interleukin-18, interleukin-18 binding protein and impaired production of interferon-gamma in chronic renal failure. Clin. Nephrol. 60, 327-334.
37. Novick, D., Schwartsburd, B., Pinkus, R., Suissa, D., Belzer, I., Sthoeger, Z., Keane, W. F., Chvatchko, Y., Kim, S. H., Fantuzzi, G., Dinarello, C. A., Rubinstein, M. (2001) A novel IL-18BP ELISA shows elevated serum IL-18BP in sepsis and extensive decrease of free IL-18. Cytokine 14, 334-342.
38. Paulukat, J., Bosmann, M., Nold, M., Garkisch, S., Kämpfer, H., Frank, S., Raedle, J., Zeuzem, S., Pfeilschifter, J., Mühl, H. (2001) Expression and release of IL-18 binding protein in response to IFN-gamma. J. Immunol. 167, 7038-7043.
39. Mühl, H., Kämpfer, H., Bosmann, M., Frank, S., Radeke, H., Pfeilschifter, J. (2000) Interferon-gamma mediates gene expression of IL-18 binding protein in nonleukocytic cells. Biochem. Biophys. Res. Commun. 267, 960-963.
40. Bachmann, M., Paulukat, J., Pfeilschifter, J., Mühl, H. (2009) Molecular mechanisms of IL-18BP regulation in DLD-1 cells: pivotal direct action of the STAT1/GAS axis on the promoter level. J. Cell. Mol. Med. 13, 1987-1994.
41. Wittmann, M., Doble, R., Bachmann, M., Pfeilschifter, J., Werfel, T., Mühl, H. (2012) IL-27 regulates IL-18 binding protein in skin resident cells. PLoS ONE 7, e38751.
42. Palma, G., Barbieri, A., Bimonte, S., Palla, M., Zappavigna, S., Caraglia, M., Ascierto, P. A., Ciliberto, G., Arra, C. (2013) Interleukin 18: friend or foe in cancer. Biochim. Biophys. Acta 1836, 296-303.
43. Dinarello, C. A. (2006) The paradox of pro-inflammatory cytokines in cancer. Cancer Metastasis Rev. 25, 307-313.
44. Hitzler, I., Sayi, A., Kohler, E., Engler, D. B., Koch, K. N., Hardt, W. D., Müller, A. (2012) Caspase-1 has both proinflammatory and regulatory properties in Helicobacter infections, which are differentially mediated by its substrates IL-1b and IL-18. J. Immunol. 188, 3594-3602.
45. Oertli, M., Sundquist, M., Hitzler, I., Engler, D. B., Arnold, I. C., Reuter, S., Maxeiner, J., Hansson, M., Taube, C., Quiding-Järbrink, M., Müller, A. (2012) DC-derived IL-18 drives Treg differentiation, murine Helicobacter pylori-specific immune tolerance, and asthma protection. J. Clin. Invest. 122, 1082-1096.
46. Tomita, T., Jackson, A. M., Hida, N., Hayat, M., Dixon, M. F., Shimoyama, T., Axon, A. T., Robinson, P. A., Crabtree, J. E. (2001) Expression of Interleukin-18, a Th1 cytokine, in human gastric mucosa is increased in Helicobacter pylori infection. J. Infect. Dis. 183, 620-627.
47. Sussman, D. A., Santaolalla, R., Strobel, S., Dheer, R., Abreu, M. T. (2012) Cancer in inflammatory bowel disease: lessons from animal models. Curr. Opin. Gastroenterol. 28, 327-333.
48. Salcedo, R., Worschech, A., Cardone, M., Jones, Y., Gyulai, Z., Dai, R. M., Wang, E., Ma, W., Haines, D., O’hUigin, C., Marincola, F. M., Trinchieri, G. (2010) MyD88-mediated signaling prevents development of adenocarcinomas of the colon: role of interleukin 18. J. Exp. Med. 207, 1625-1636.
49. Zaki, M. H., Vogel, P., Body-Malapel, M., Lamkanfi, M., Kanneganti, T. D. (2010) IL-18 production downstream of the Nlrp3 inflammasome confers protection against colorectal tumor formation. J. Immunol. 185, 4912-4920.
50. Nishio, S., Yamada, N., Ohyama, H., Yamanegi, K., Nakasho, K., Hata, M., Nakamura, Y., Fukunaga, S., Futani, H., Yoshiya, S., Ueda, H., Taniguchi, M., Okamura, H., Terada, N. (2008) Enhanced suppression of pulmonary metastasis of malignant melanoma cells by combined administration of alpha-galactosylceramide and interleukin-18. Cancer Sci. 99, 113-120.
51. Osaki, T., Péron, J. M., Cai, Q., Okamura, H., Robbins, P. D., Kurimoto, M., Lotze, M. T., Tahara, H. (1998) IFN-gamma-inducing factor/IL-18 administration mediates IFN-gamma- and IL-12-independent antitumor effects. J. Immunol. 160, 1742-1749.
52. Coughlin, C. M., Salhany, K. E., Wysocka, M., Aruga, E., Kurzawa, H., Chang, A. E., Hunter, C. A., Fox, J. C., Trinchieri, G., Lee, W.M. (1998) Interleukin- 12 and interleukin-18 synergistically induce murine tumor regression which involves inhibition of angiogenesis. J. Clin. Invest. 101, 1441-1452.
53. Nagai, H., Hara, I., Horikawa, T., Oka, M., Kamidono, S., Ichihashi, M. (2002) Gene transfer of secreted-type modified interleukin-18 gene to B16F10 melanoma cells suppresses in vivo tumor growth through inhibition of tumor vessel formation. J. Invest. Dermatol. 119, 541-548.
54. Cho, D., Kim, T. G., Lee, W., Hwang, Y. I., Cho, H. I., Han, H., Kwon, O., Kim, D., Park, H., Houh, D. (2000) Interleukin-18 and the costimulatory molecule B7-1 have a synergistic anti-tumor effect on murine melanoma; implication of combined immunotherapy for poorly immunogenic malignancy. J. Invest. Dermatol. 114, 928-934.
55. Choi, I. K., Lee, J. S., Zhang, S. N., Park, J., Sonn, C. H., Lee, K. M., Yun, C. O. (2011) Oncolytic adenovirus co-expressing IL-12 and IL-18 improves tumor-specific immunity via differentiation of T cells expressing IL-12Rb2 or IL-18Ra. Gene Ther. 18, 898-909.
56. Tian, H., Shi, G., Yang, G., Zhang, J., Li, Y., Du, T., Wang, J., Xu, F., Cheng, L., Zhang, X., Dai, L., Chen, X., Zhang, S., Yang, Y., Yu, D., Wei, Y., Deng, H. (2014) Cellular immunotherapy using irradiated lung cancer cell vaccine co-expressing GM-CSF and IL-18 can induce significant antitumor effects. BMC Cancer 14, 48.
57. Shi, F. F., Gunn, G. R., Snyder, L. A., Goletz, T. J. (2007) Intradermal vaccination of MUC1 transgenic mice with MUC1/IL-18 plasmid DNA suppresses experimental pulmonary metastases. Vaccine 25, 3338-3346.
58. Loeffler, M., Le’Negrate, G., Krajewska, M., Reed, J. C. (2008) IL-18- producing Salmonella inhibit tumor growth. Cancer Gene Ther. 15, 787-794.
59. Ni, J., Miller, M., Stojanovic, A., Garbi, N., Cerwenka, A. (2012) Sustained effector function of IL-12/15/18-preactivated NK cells against established tumors. J. Exp. Med. 209, 2351-2365.
60. Srivastava, S., Pelloso, D., Feng, H., Voiles, L., Lewis, D., Haskova, Z., Whitacre, M., Trulli, S., Chen, Y. J., Toso, J., Jonak, Z. L., Chang, H. C., Robertson, M. J. (2013) Effects of interleukin-18 on natural killer cells: costimulation of activation through Fc receptors for immunoglobulin. Cancer Immunol. Immunother. 62, 1073-1082.
61. Srivastava, S., Salim, N., Robertson, M. J. (2010) Interleukin-18: biology and role in the immunotherapy of cancer. Curr. Med. Chem. 17, 3353-3357.
62. Ino, Y., Saeki, Y., Fukuhara, H., Todo, T. (2006) Triple combination of oncolytic herpes simplex virus-1 vectors armed with interleukin-12, interleukin-18, or soluble B7-1 results in enhanced antitumor efficacy. Clin. Cancer Res. 12, 643-652.
63. Acres, B., Gantzer, M., Remy, C., Futin, N., Accart, N., Chaloin, O., Hoebeke, J., Balloul, J. M., Paul, S. (2005) Fusokine interleukin-2/ interleukin-18, a novel potent innate and adaptive immune stimulator with decreased toxicity. Cancer Res. 65, 9536-9546.
64. Cooper, M. A., Elliott, J. M., Keyel, P. A., Yang, L., Carrero, J. A., Yokoyama, W. M. (2009) Cytokine-induced memory-like natural killer cells. Proc. Natl. Acad. Sci. USA 106, 1915-1919.
65. Romee, R., Schneider, S. E., Leong, J. W., Chase, J. M., Keppel, C. R., Sullivan, R. P., Cooper, M. A., Fehniger, T. A. (2012) Cytokine activation induces human memory-like NK cells. Blood 120, 4751-4760.
66. Leong, J. W., Chase, J. M., Romee, R., Schneider, S. E., Sullivan, R. P., Cooper, M. A., Fehniger, T. A. (2014) Preactivation with IL-12, IL-15, and IL-18 induces CD25 and a functional high-affinity IL-2 receptor on human cytokine-induced memory-like natural killer cells. Biol. Blood Marrow Transplant. 20, 463-473.
67. Wong, J. L., Muthuswamy, R., Bartlett, D. L., Kalinski, P. (2013) IL-18- based combinatorial adjuvants promote the intranodal production of CCL19 by NK cells and dendritic cells of cancer patients. OncoImmunology 2, e26245.
68. Pagès, F., Berger, A., Henglein, B., Piqueras, B., Danel, C., Zinzindohoue, F., Thiounn, N., Cugnenc, P. H., Fridman, W. H. (1999) Modulation of interleukin-18 expression in human colon carcinoma: consequences for tumor immune surveillance. Int. J. Cancer 84, 326-330.
69. Wang, Z. Y., Gaggero, A., Rubartelli, A., Rosso, O., Miotti, S., Mezzanzanica, D., Canevari, S., Ferrini, S. (2002) Expression of interleukin-18 in human ovarian carcinoma and normal ovarian epithelium: evidence for defective processing in tumor cells. Int. J. Cancer 98, 873-878.
70. Feng, Q., Li, P., Salamanca, C., Huntsman, D., Leung, P. C., Auersperg, N. (2005) Caspase-1alpha is down-regulated in human ovarian cancer cells and the overexpression of caspase-1alpha induces apoptosis. Cancer Res. 65, 8591-8596.
71. Gaggero, A., De Ambrosis, A., Mezzanzanica, D., Piazza, T., Rubartelli, A., Figini, M., Canevari, S., Ferrini, S. (2004) A novel isoform of pro-interleukin-18 expressed in ovarian tumors is resistant to caspase-1 and -4 processing. Oncogene 23, 7552-7560.
72. Orengo, A. M., Fabbi, M., Miglietta, L., Andreani, C., Bruzzone, M., Puppo, A., Cristoforoni, P., Centurioni, M. G., Gualco, M., Salvi, S., Boccardo, S., Truini, M., Piazza, T., Canevari, S., Mezzanzanica, D., Ferrini, S. (2011) Interleukin (IL)-18, a biomarker of human ovarian carcinoma, is predominantly released as biologically inactive precursor. Int. J. Cancer 129, 1116-1125.
73. Fujita, K., Ewing, C. M., Isaacs, W. B., Pavlovich, C. P. (2011) Immunomodulatory IL-18 binding protein is produced by prostate cancer cells and its levels in urine and serum correlate with tumor status. Int. J. Cancer 129, 424-432.
74. Carbotti, G., Barisione, G., Orengo, A. M., Brizzolara, A., Airoldi, I., Bagnoli, M., Pinciroli, P., Mezzanzanica, D., Centurioni, M. G., Fabbi, M., Ferrini, S. (2013) The IL-18 antagonist IL-18-binding protein is produced in the human ovarian cancer microenvironment. Clin. Cancer Res. 19, 4611-4620.
75. Spranger, S., Spaapen, R. M., Zha, Y., Williams, J., Meng, Y., Ha, T. T., Gajewski, T. F. (2013) Up-regulation of PD-L1, IDO, and T(regs) in the melanoma tumor microenvironment is driven by CD8(+) T cells. Sci. Transl. Med. 5, 200ra116.
76. Robertson, M. J., Mier, J. W., Logan, T., Atkins, M., Koon, H., Koch, K. M., Kathman, S., Pandite, L. N., Oei, C., Kirby, L. C., Jewell, R. C., Bell, W. N., Thurmond, L. M., Weisenbach, J., Roberts, S., Dar, M. M. (2006) Clinical and biological effects of recombinant human interleukin-18 administered by intravenous infusion to patients with advanced cancer. Clin. Cancer Res. 12, 4265-4273.
77. Robertson, M. J., Kirkwood, J. M., Logan, T. F., Koch, K. M., Kathman, S., Kirby, L. C., Bell, W. N., Thurmond, L. M., Weisenbach, J., Dar, M. M. (2008) A dose-escalation study of recombinant human interleukin-18 using two different schedules of administration in patients with cancer. Clin. Cancer Res. 14, 3462-3469.
78. Tarhini, A. A., Millward, M., Mainwaring, P., Kefford, R., Logan, T., Pavlick, A., Kathman, S. J., Laubscher, K. H., Dar, M. M., Kirkwood, J. M. (2009) A phase 2, randomized study of SB-485232, rhIL-18, in patients with previously untreated metastatic melanoma. Cancer 115, 859-868.
79. Robertson, M. J., Kline, J., Struemper, H., Koch, K. M., Bauman, J. W., Gardner, O. S., Murray, S. C., Germaschewski, F., Weisenbach, J., Jonak, Z., Toso, J. F. (2013) A dose-escalation study of recombinant human interleukin-18 in combination with rituximab in patients with non- Hodgkin lymphoma. J. Immunother. 36, 331-341.
80. Simpkins, F., Flores, A., Chu, C., Berek, J. S., Lucci III J., Murray, S., Bauman, J., Struemper, H., Germaschewski, F., Jonak, Z., Gardner, O., Toso, J., Coukos, G. (2013) Chemoimmunotherapy using pegylated liposomal doxorubicin and interleukin-18 in recurrent ovarian cancer: a phase I dose-escalation study. Cancer Immunol. Res. 1, 168-178.
81. Kim, J., Kim, C., Kim, T. S., Bang, S. I., Yang, Y., Park, H., Cho, D. (2006) IL-18 enhances thrombospondin-1 production in human gastric cancer via JNK pathway. Biochem. Biophys. Res. Commun. 344, 1284-1289.
82. Kim, K. E., Song, H., Kim, T. S., Yoon, D., Kim, C. W., Bang, S. I., Hur, D. Y., Park, H., Cho, D. H. (2007) Interleukin-18 is a critical factor for vascular endothelial growth factor-enhanced migration in human gastric cancer cell lines. Oncogene 26, 1468-1476.
83. Kim, K. E., Song, H., Hahm, C., Yoon, S. Y., Park, S., Lee, H. R., Hur, D. Y., Kim, T., Kim, C. H., Bang, S. I., Bang, J. W., Park, H., Cho, D. H. (2009) Expression of ADAM33 is a novel regulatory mechanism in IL- 18-secreted process in gastric cancer. J. Immunol. 182, 3548-3555.
84. Majima, T., Ichikura, T., Chochi, K., Kawabata, T., Tsujimoto, H., Sugasawa, H., Kuranaga, N., Takayama, E., Kinoshita, M., Hiraide, H., Seki, S., Mochizuki, H. (2006) Exploitation of interleukin-18 by gastric cancers for their growth and evasion of host immunity. Int. J. Cancer 118, 388-395.
85. Uzan, B., Poglio, S., Gerby, B., Wu, C. L., Gross, J., Armstrong, F., Calvo, J., Cahu, X., Deswarte, C., Dumont, F., Passaro, D., Besnard-Guérin, C., Leblanc, T., Baruchel, A., Landman-Parker, J., Ballerini, P., Baud, V., Ghysdael, J., Baleydier, F., Porteu, F., Pflumio, F. (2014) Interleukin-18 produced by bone marrow-derived stromal cells supports T-cell acute leukaemia progression. EMBO Mol. Med. 6, 821-834.
86. Terme, M., Ullrich, E., Aymeric, L., Meinhardt, K., Desbois, M., Delahaye, N., Viaud, S., Ryffel, B., Yagita, H., Kaplanski, G., Prévost- Blondel, A., Kato, M., Schultze, J. L., Tartour, E., Kroemer, G., Chaput, N., Zitvogel, L. (2011) IL-18 induces PD-1-dependent immunosuppression in cancer. Cancer Res. 71, 5393-5399.
87. Terme, M., Ullrich, E., Aymeric, L., Meinhardt, K., Coudert, J. D., Desbois, M., Ghiringhelli, F., Viaud, S., Ryffel, B., Yagita, H., Chen, L., Mécheri, S., Kaplanski, G., Prévost-Blondel, A., Kato, M., Schultze, J. L., Tartour, E., Kroemer, G., Degli-Esposti, M., Chaput, N., Zitvogel, L. (2012) Cancer-induced immunosuppression: IL-18-elicited immunoablative NK cells. Cancer Res. 72, 2757-2767.
88. Lim, H. X., Hong, H. J., Cho, D., Kim, T. S. (2014) IL-18 enhances immunosuppressive responses by promoting differentiation into monocytic myeloid-derived suppressor cells. J. Immunol. 193, 5453-5460.
89. Gosmann, C., Frazer, I. H., Mattarollo, S. R., Blumenthal, A. (2014) IL-18, but not IL-12, induces production of IFN-g in the immunosuppressive environment of HPV16 E7 transgenic hyperplastic skin. J. Invest. Dermatol. 134, 2562-2569.
90. Vidal-Vanaclocha, F., Fantuzzi, G., Mendoza, L., Fuentes, A. M., Anasagasti, M. J., Martín, J., Carrascal, T., Walsh, P., Reznikov, L. L., Kim, S. H., Novick, D., Rubinstein, M., Dinarello, C. A. (2000) IL-18 regulates IL-1beta-dependent hepatic melanoma metastasis via vascular cell adhesion molecule-1. Proc. Natl. Acad. Sci. USA 97, 734-739.
91. Carrascal, M. T., Mendoza, L., Valcárcel, M., Salado, C., Egilegor, E., Tellería, N., Vidal-Vanaclocha, F., Dinarello, C. A. (2003) Interleukin-18 binding protein reduces b16 melanoma hepatic metastasis by neutralizing adhesiveness and growth factors of sinusoidal endothelium. Cancer Res. 63, 491-497.
92. Salado, C., Olaso, E., Gallot, N., Valcarcel, M., Egilegor, E., Mendoza, L., Vidal-Vanaclocha, F. (2011) Resveratrol prevents inflammationdependent hepatic melanoma metastasis by inhibiting the secretion and effects of interleukin-18. J. Transl. Med. 9, 59.
93. Ahmad, I., Muneer, K. M., Tamimi, I. A., Chang, M. E., Ata, M. O., Yusuf, N. (2013) Thymoquinone suppresses metastasis of melanoma cells by inhibition of NLRP3 inflammasome. Toxicol. Appl. Pharmacol. 270, 70-76.
94. Valcárcel, M., Carrascal, T., Crende, O., Vidal-Vanaclocha, F. (2014) IL-18 regulates melanoma VLA-4 integrin activation through a hierarchized sequence of inflammatory factors. J. Invest. Dermatol. 134, 470-480.
95. Crende, O., Sabatino, M., Valcárcel, M., Carrascal, T., Riestra, P., López- Guerrero, J. A., Nagore, E., Mandruzzato, S., Wang, E., Marincola, F. M., Vidal-Vanaclocha, F. (2013) Metastatic lesions with and without interleukin-18-dependent genes in advanced-stage melanoma patients. Am. J. Pathol. 183, 69-82.
96. Wang, M., Zhu, X. Y., Wang, L., Lin, Y. (2013) The 2607C/A polymorphisms in interleukin-18 gene promoter contributes to cancer risk: evidence from a meta-analysis of 22 case-control studies. PLoS ONE 8, e76915.
97. Yang X, Qiu, M T., Hu, J. W., Jiang, F., Li, M., Wang, J., Zhang, Q., Yin, R., Xu, L. (2013) Association of interleukin-18 gene promoter 2607 C.A and 2137G.C polymorphisms with cancer risk: a meta-analysis of 26 studies. PLoS ONE 8, e73671.
98. Shibatomi, K., Ida, H., Yamasaki, S., Nakashima, T., Origuchi, T., Kawakami, A., Migita, K., Kawabe, Y., Tsujihata, M., Anderson, P., Eguchi, K. (2001) A novel role for interleukin-18 in human natural killer cell death: high serum levels and low natural killer cell numbers in patients with systemic autoimmune diseases. Arthritis Rheum. 44, 884-892.
99. Cao, Q., Cai, W., Niu, G., He, L., Chen, X. (2008) Multimodality imaging of IL-18-binding protein-Fc therapy of experimental lung metastasis. Clin. Cancer Res. 14, 6137-6145.
100. Giedraitis, V., He, B., Huang, W. X., Hillert, J. (2001) Cloning and mutation analysis of the human IL-18 promoter: a possible role of polymorphisms in expression regulation. J. Neuroimmunol. 112, 146-152.
101. Tsuboi, K., Miyazaki, T., Nakajima, M., Fukai, Y., Masuda, N., Manda, R., Fukuchi, M., Kato, H., Kuwano, H. (2004) Serum interleukin-12 and interleukin-18 levels as a tumor marker in patients with esophageal carcinoma. Cancer Lett. 205, 207-214.
102. Ye, Z. B., Ma, T., Li, H., Jin, X. L., Xu, H. M. (2007) Expression and significance of intratumoral interleukin-12 and interleukin-18 in human gastric carcinoma. World J. Gastroenterol. 13, 1747-1751.
103. Günel, N., Coşkun, U., Sancak, B., Günel, U., Hasdemir, O., Bozkurt, S. (2002) Clinical importance of serum interleukin-18 and nitric oxide activities in breast carcinoma patients. Cancer 95, 663-667.
104. Le Page, C., Ouellet, V., Madore, J., Hudson, T. J., Tonin, P. N., Provencher, D. M., Mes-Masson, A. M. (2006) From gene profiling to diagnostic markers: IL-18 and FGF-2 complement CA125 as serumbased markers in epithelial ovarian cancer. Int. J. Cancer 118, 1750-1758.
105. Carbone, A., Vizio, B., Novarino, A., Mauri, F. A., Geuna, M., Robino, C., Brondino, G., Prati, A., Giacobino, A., Campra, D., Chiarle, R., Fronda, G. R., Ciuffreda, L., Bellone, G. (2009) IL-18 paradox in pancreatic carcinoma: elevated serum levels of free IL-18 are correlated with poor survival. J. Immunother. 32, 920-931.
106. Asakawa, M., Kono, H., Amemiya, H., Matsuda, M., Suzuki, T., Maki, A., Fujii, H. (2006) Role of interleukin-18 and its receptor in hepatocellular carcinoma associated with hepatitis C virus infection. Int. J. Cancer 118, 564-570.
107. Naumnik, W., Chyczewska, E., Kovalchuk, O., Tałałaj, J., Izycki, T., Panek, B. (2004) Serum levels of interleukin-18 (IL-18) and soluble interleukin-2 receptor (sIL-2R) in lung cancer. Rocz. Akad. Med. Bialymst. 49, 246-251.
108. Sözen, S., Coskun, U., Sancak, B., Bukan, N., Günel, N., Tunc, L., Bozkirli, I. (2004) Serum levels of interleukin-18 and nitrite+nitrate in renal cell carcinoma patients with different tumor stage and grade. Neoplasma 51, 25-29.
109. Goto, N., Tsurumi, H., Kasahara, S., Kanemura, N., Hara, T., Yasuda, I., Shimizu, M., Murakami, N., Sawada, M., Yamada, T., Takemura, M., Seishima, M., Kito, Y., Takami, T., Moriwaki, H. (2011) Serum interleukin-18 level is associated with the outcome of patients with diffuse large B-cell lymphoma treated with CHOP or R-CHOP regimens. Eur. J. Haematol. 87, 217-227.
110. Alexandrakis, M. G., Passam, F. H., Sfiridaki, K., Moschandrea, J., Pappa, C., Liapi, D., Petreli, E., Roussou, P., Kyriakou, D. S. (2004) Interleukin- 18 in multiple myeloma patients: serum levels in relation to response to treatment and survival. Leuk. Res. 28, 259-266.
111. Carbone, A., Rodeck, U., Mauri, F. A., Sozzi, M., Gaspari, F., Smirne, C., Prati, A., Addeo, A., Novarino, A., Robecchi, A., Bertetto, O., Emanuelli, G., Bellone, G. (2005) Human pancreatic carcinoma cells secrete bioactive interleukin-18 after treatment with 5-fluorouracil: implications for anti-tumor immune response. Cancer Biol. Ther. 4, 231-241